{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T05:48:30Z","timestamp":1761630510618},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2009,2,1]],"date-time":"2009-02-01T00:00:00Z","timestamp":1233446400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med Klin"],"published-print":{"date-parts":[[2009,2]]},"DOI":"10.1007\/s00063-009-1024-8","type":"journal-article","created":{"date-parts":[[2009,2,25]],"date-time":"2009-02-25T07:21:36Z","timestamp":1235546496000},"page":"125-136","source":"Crossref","is-referenced-by-count":11,"title":["Behandlung der Plaque-Psoriasis mit Biologics"],"prefix":"10.1007","volume":"104","author":[{"given":"Zhengguang","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jochen","family":"Schmitt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gottfried","family":"Wozel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wilhelm","family":"Kirch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,2,26]]},"reference":[{"issue":"Suppl2","key":"1024_CR1","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1111\/j.1610-0387.2006.06172.x","volume":"4","author":"A. Nast","year":"2006","unstructured":"Nast A, Kopp IB, Augustin M, et al. [S3-guidelines for the therapy of psoriasis vulgaris.] J Dtsch Dermatol Ges 2006;4:Suppl 2:S1\u2013126.","journal-title":"J Dtsch Dermatol Ges"},{"key":"1024_CR2","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/S0190-9622(97)70172-5","volume":"37","author":"S.R. Feldman","year":"1997","unstructured":"Feldman SR, Fleischer ABJr, Reboussin DM, et al. The economic impact of psoriasis increases with psoriasis severity. J Am Acad Dermatol 1997;37:564\u20139.","journal-title":"J Am Acad Dermatol"},{"key":"1024_CR3","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1159\/000093848","volume":"213","author":"J. Schmitt","year":"2006","unstructured":"Schmitt J, Ford DE. Work limitations and productivity loss are associated with health-related quality of life but not with clinical severity in patients with psoriasis. Dermatology 2006;213:102\u201310.","journal-title":"Dermatology"},{"key":"1024_CR4","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1159\/000090654","volume":"212","author":"S. Sohn","year":"2006","unstructured":"Sohn S, Schoeffski O, Prinz J, et al. Cost of moderate to severe plaque psoriasis in Germany: a multicenter cost-of-illness study. Dermatology 2006;212:137\u201344.","journal-title":"Dermatology"},{"key":"1024_CR5","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1023\/B:EJEP.0000020447.59150.f9","volume":"19","author":"L. Mallbris","year":"2004","unstructured":"Mallbris L, Akre O, Granath F, et al. Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients. Eur J Epidemiol 2004;19:225\u201330.","journal-title":"Eur J Epidemiol"},{"key":"1024_CR6","first-page":"1493","volume":"143","author":"J.M. Gelfand","year":"2007","unstructured":"Gelfand JM, Troxel AB, Lewis JD, et al. The risk of mortality in patients with psoriasis: results from a population-based study. Arch Dermatol 2007;143:1493\u20139.","journal-title":"Arch Dermatol"},{"key":"1024_CR7","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1159\/000102029","volume":"215","author":"J.M. Schmitt","year":"2007","unstructured":"Schmitt JM, Ford DE. Role of depression in quality of life for patients with psoriasis. Dermatology 2007;215:17\u201327.","journal-title":"Dermatology"},{"key":"1024_CR8","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1111\/j.1610-0387.2007.06343.x","volume":"5","author":"K. Reich","year":"2007","unstructured":"Reich K, Mrowietz U. Treatment goals in psoriasis. J Dtsch Dermatol Ges 2007;5:566\u201374.","journal-title":"J Dtsch Dermatol Ges"},{"key":"1024_CR9","volume-title":"Biologics in der Dermatologie","author":"G. Wozel","year":"2006","unstructured":"Wozel G, Jahn S, Hrsg. Biologics in der Dermatologie, 2. Aufl. Bremen-London-Boston: Uni-Med, 2006."},{"key":"1024_CR10","first-page":"Doc07","volume":"2","author":"C. Claes","year":"2006","unstructured":"Claes C, Kulp W, Greiner W, et al. Therapie der mittelschweren und der schweren Psoriasis. GMS Health Technol Assess 2006;2:Doc07.","journal-title":"GMS Health Technol Assess"},{"key":"1024_CR11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta4400","volume":"4","author":"C.E. Griffiths","year":"2000","unstructured":"Griffiths CE, Clark CM, Chalmers RJ, et al. A systematic review of treatments for severe psoriasis. Health Technol Assess 2000;4:1\u2013125.","journal-title":"Health Technol Assess"},{"key":"1024_CR12","doi-asserted-by":"crossref","unstructured":"Woolacott N, Hawkins N, Mason A, et al. Etanercept and efalizumab for the treatment of psoriasis: a systematic review. Health Technol Assess 2006;10(46).","DOI":"10.3310\/hta10460"},{"key":"1024_CR13","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1159\/000250839","volume":"157","author":"T. Fredriksson","year":"1978","unstructured":"Fredriksson T, Pettersson U. Severe psoriasis-oral therapy with a new retinoid. Dermatologica 1978;157:238\u201344.","journal-title":"Dermatologica"},{"key":"1024_CR14","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/1477-7525-1-53","volume":"1","author":"R. Shikiar","year":"2003","unstructured":"Shikiar R, Bresnahan BW, Stone SP, et al. Validity and reliability of patient reported outcomes used in psoriasis: results from two randomized clinical trials. Health Qual Life Outcomes 2003;1:53.","journal-title":"Health Qual Life Outcomes"},{"key":"1024_CR15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","volume":"17","author":"A.R. Jadad","year":"1996","unstructured":"Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996;17:1\u201312.","journal-title":"Control Clin Trials"},{"key":"1024_CR16","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1159\/000083509","volume":"210","author":"J. Schmitt","year":"2005","unstructured":"Schmitt J, Wozel G. The psoriasis area and severity index is the adequate criterion to define severity in chronic plaque-type psoriasis. Dermatology 2005;210:194\u20139.","journal-title":"Dermatology"},{"key":"1024_CR17","volume-title":"Systematic reviews in health care. Meta-analysis in context","author":"M. Egger","year":"2003","unstructured":"Egger M, Smith GD, Altman DG. Systematic reviews in health care. Meta-analysis in context. London: BMJ, 2003."},{"key":"1024_CR18","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1016\/S0140-6736(00)04954-0","volume":"357","author":"U. Chaudhari","year":"2001","unstructured":"Chaudhari U, Romano P, Mulcahy LD, et al. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 2001;357:1842\u20137.","journal-title":"Lancet"},{"key":"1024_CR19","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.jaad.2004.02.021","volume":"51","author":"A.B. Gottlieb","year":"2004","unstructured":"Gottlieb AB, Evans R, Li S, et al. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol 2004;51:534\u201342.","journal-title":"J Am Acad Dermatol"},{"key":"1024_CR20","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1111\/j.1365-2133.2005.06510.x","volume":"152","author":"S.R. Feldman","year":"2005","unstructured":"Feldman SR, Gordon KB, Bala M, et al. Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial. Br J Dermatol 2005;152:954\u201360.","journal-title":"Br J Dermatol"},{"key":"1024_CR21","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/S0140-6736(05)67566-6","volume":"366","author":"K. Reich","year":"2005","unstructured":"Reich K, Nestle FO, Papp K, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 2005;366:1367\u201374.","journal-title":"Lancet"},{"key":"1024_CR22","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1111\/j.1365-2133.2006.07237.x","volume":"154","author":"K. Reich","year":"2006","unstructured":"Reich K, Nestle FO, Papp K, et al. Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis: a randomized controlled trial. Br J Dermatol 2006;154:1161\u20138.","journal-title":"Br J Dermatol"},{"issue":"31","key":"1024_CR23","first-page":"e1","volume":"56","author":"A. Menter","year":"2007","unstructured":"Menter A, Feldman SR, Weinstein GD, et al. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol 2007;56:31.e1\u201315.","journal-title":"J Am Acad Dermatol"},{"key":"1024_CR24","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1056\/NEJMoa030409","volume":"349","author":"C.L. Leonardi","year":"2003","unstructured":"Leonardi CL, Powers JL, Matheson RT, et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003;349:2014\u201322.","journal-title":"N Engl J Med"},{"key":"1024_CR25","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.jaad.2005.06.053","volume":"53","author":"S.R. Feldman","year":"2005","unstructured":"Feldman SR, Kimball AB, Krueger GG, et al. Etanercept improves the health-related quality of life of patients with psoriasis: results of a phase III randomized clinical trial. J Am Acad Dermatol 2005;53: 887\u20139.","journal-title":"J Am Acad Dermatol"},{"key":"1024_CR26","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1001\/archderm.139.12.1627","volume":"139","author":"A.B. Gottlieb","year":"2003","unstructured":"Gottlieb AB, Matheson RT, Lowe N, et al. A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol 2003;139:1627\u201332.","journal-title":"Arch Dermatol"},{"key":"1024_CR27","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1111\/j.1365-2133.2005.06688.x","volume":"152","author":"K.A. Papp","year":"2005","unstructured":"Papp KA, Tyring S, Lahfa M, et al. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol 2005;152:1304\u201312.","journal-title":"Br J Dermatol"},{"key":"1024_CR28","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1111\/j.1365-2133.2005.06948.x","volume":"153","author":"G.G. Krueger","year":"2005","unstructured":"Krueger GG, Langley RG, Finlay AY, et al. Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial. Br J Dermatol 2005;153:1192\u20139.","journal-title":"Br J Dermatol"},{"key":"1024_CR29","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(05)67763-X","volume":"367","author":"S. Tyring","year":"2006","unstructured":"Tyring S, Gottlieb A, Papp K, et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet 2006;367:29\u201335.","journal-title":"Lancet"},{"key":"1024_CR30","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1001\/archderm.143.6.719","volume":"143","author":"S. Tyring","year":"2007","unstructured":"Tyring S, Gordon KB, Poulin Y, et al. Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis. Arch Dermatol 2007;143:719\u201326.","journal-title":"Arch Dermatol"},{"key":"1024_CR31","first-page":"225","volume":"19","author":"N. Cassano","year":"2006","unstructured":"Cassano N, Loconsole F, Galluccio A, et al. Once-weekly administration of high-dosage etanercept in patients with plaque psoriasis: results of a pilot experience (power study). Int J Immunopathol Pharmacol 2006;19:225\u20139.","journal-title":"Int J Immunopathol Pharmacol"},{"key":"1024_CR32","doi-asserted-by":"crossref","first-page":"3073","DOI":"10.1001\/jama.290.23.3073","volume":"290","author":"K.B. Gordon","year":"2003","unstructured":"Gordon KB, Papp KA, Hamilton TK, et al. Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. JAMA 2003;290:3073\u201380.","journal-title":"JAMA"},{"key":"1024_CR33","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1001\/archderm.141.1.31","volume":"141","author":"A. Menter","year":"2005","unstructured":"Menter A, Gordon K, Carey W, et al. Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis. Arch Dermatol 2005;141:31\u20138.","journal-title":"Arch Dermatol"},{"key":"1024_CR34","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1056\/NEJMoa030002","volume":"349","author":"M. Lebwohl","year":"2003","unstructured":"Lebwohl M, Tyring SK, Hamilton TK, et al. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med 2003;349:2004\u201313.","journal-title":"N Engl J Med"},{"key":"1024_CR35","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.jaad.2004.09.029","volume":"52","author":"C.L. Leonardi","year":"2005","unstructured":"Leonardi CL, Papp KA, Gordon KB, et al. Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial. J Am Acad Dermatol 2005;52:425\u201333.","journal-title":"J Am Acad Dermatol"},{"key":"1024_CR36","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1111\/j.1365-4632.2006.02777.x","volume":"45","author":"K.A. Papp","year":"2006","unstructured":"Papp KA, Bressinck R, Fretzin S, et al. Safety of efalizumab in adults with chronic moderate to severe plaque psoriasis: a phase IIIb, randomized, controlled trial. Int J Dermatol 2006;45:605\u201314.","journal-title":"Int J Dermatol"},{"key":"1024_CR37","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/j.1365-2133.2006.07344.x","volume":"155","author":"L. Dubertret","year":"2006","unstructured":"Dubertret L, Sterry W, Bos JD, et al. Clinical Experience Acquired with the Efalizumab (Raptiva) (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from a phase III international randomized, placebo-controlled trial. Br J Dermatol 2006;155:170\u201381.","journal-title":"Br J Dermatol"},{"key":"1024_CR38","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1471-5945-5-13","volume":"5","author":"J.P. Ortonne","year":"2005","unstructured":"Ortonne JP, Shear N, Shumack S, et al. Impact of efalizumab on patient-reported outcomes in high-need psoriasis patients: results of the international, randomized, placebo-controlled phase III Clinical Experience Acquired with Raptiva (CLEAR) trial [NCT00256139]. BMC Dermatol 2005;5:13.","journal-title":"BMC Dermatol"},{"key":"1024_CR39","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.jaad.2006.05.027","volume":"55","author":"K.B. Gordon","year":"2006","unstructured":"Gordon KB, Langley RG, Leonardi C, et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol 2006;55:598\u2013606.","journal-title":"J Am Acad Dermatol"},{"key":"1024_CR40","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/1477-7525-4-71","volume":"4","author":"R. Shikiar","year":"2006","unstructured":"Shikiar R, Willian MK, Okun MM, et al. The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients: results of a phase II study. Health Qual Life Outcomes 2006;4:71.","journal-title":"Health Qual Life Outcomes"},{"key":"1024_CR41","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1080\/09546630601121060","volume":"18","author":"R. Shikiar","year":"2007","unstructured":"Shikiar R, Heffernan M, Langley RG, et al. Adalimumab treatment is associated with improvement in health-related quality of life in psoriasis: patient-reported outcomes from a phase II randomized controlled trial. J Dermatol Treat 2007;18:25\u201331.","journal-title":"J Dermatol Treat"},{"key":"1024_CR42","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jaad.2007.09.010","volume":"58","author":"A. Menter","year":"2008","unstructured":"Menter A, Tyring SK, Gordon K, et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol 2008;58:106\u201315.","journal-title":"J Am Acad Dermatol"},{"key":"1024_CR43","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/j.1365-2133.2007.08315.x","volume":"158","author":"J.H. Saurat","year":"2008","unstructured":"Saurat JH, Stingl G, Dubertret L, et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol 2008;158:558\u201366.","journal-title":"Br J Dermatol"},{"key":"1024_CR44","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa066886","volume":"358","author":"A.S. Paller","year":"2008","unstructured":"Paller AS, Paller AS, Siegfried EC, et al. Etanercept treatment for children and adolescents with plaque psoriasis. N Engl J Med 2008;358:241\u201351.","journal-title":"N Engl J Med"},{"key":"1024_CR45","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S0190-9622(99)70112-X","volume":"41","author":"S.R. Rapp","year":"1999","unstructured":"Rapp SR, Feldman SR, Exum ML, et al. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999;41:401\u20137.","journal-title":"J Am Acad Dermatol"},{"key":"1024_CR46","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1111\/j.1365-2133.2005.06502.x","volume":"152","author":"A.Y. Finlay","year":"2005","unstructured":"Finlay AY. Current severe psoriasis and the rule of tens. Br J Dermatol 2005;152:861\u20137.","journal-title":"Br J Dermatol"},{"key":"1024_CR47","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/S0140-6736(08)60571-1","volume":"371","author":"L. Naldi","year":"2008","unstructured":"Naldi L. The search for effective and safe disease control in psoriasis. Lancet 2008;371:1311\u20132.","journal-title":"Lancet"}],"container-title":["Medizinische Klinik"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00063-009-1024-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00063-009-1024-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00063-009-1024-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T02:13:21Z","timestamp":1558577601000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00063-009-1024-8"}},"subtitle":["Eine Metaanalyse randomisierter kontrollierter Studien"],"short-title":[],"issued":{"date-parts":[[2009,2]]},"references-count":47,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009,2]]}},"alternative-id":["1024"],"URL":"https:\/\/doi.org\/10.1007\/s00063-009-1024-8","relation":{},"ISSN":["0723-5003","1615-6722"],"issn-type":[{"value":"0723-5003","type":"print"},{"value":"1615-6722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,2]]}}}